Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The BIIB800 Candidate Is Only the Latest Of Biogen’s Deal-Driven Biosimilars

Executive Summary

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

You may also be interested in...

Biosimilars Growth At Biogen Still Pending As Unfavorable Market Takes Its Toll

Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.

Fresenius Files Tocilizumab Biosimilar With EMA

Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.

Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar

Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts